Johanna Mattson, MD, PhD, is the Director and Physician-in-Chief at the Helsinki University Hospital Comprehensive Cancer Center. She also works as an Adjunct Professor at the University of Helsinki. Johanna received her MD degree in 1991 and PhD in 2000 from the University of Helsinki. Since 1993 she has been working at the Cancer Center, Helsinki University Hospital except for the year 2000 when she served as Medical Advisor at Aventis Pharma. During 2017–18 she conducted the Managing Healthcare Delivery program at Harvard Business School. Her main clinical and scientific interest is in the treatment of breast cancer. Johanna has developed mobile software for patient-reported outcomes during cancer therapies and follow-up.
Tarja Jalava holds a PhD in Biochemistry from Helsinki University, Finland. She has over 20 years of experience in Global Clinical Research with a special focus on oncology. Today, Tarja Jalava is Director, Head Clinical Project Management II, Oncology Strategic Business Unit at Bayer and in charge of executing high quality global clinical programs and trials in oncology. In addition, one of her activities is promoting Finnish innovation opportunities, especially in oncology, at Bayer.
Visa Honkanen MD, PhD, Chief Digital Officer, is responsible for the digital disruption and the lean turnaround which has occurred at the HUS Helsinki University Hospital. His work focuses on digitalization, eHealth, and AI development for clinical use. His research interest has focused on focused on clinical studies and experimental statistics. For his work on eHealth, he received the Finnish Healthcare Influencer of the Year award in 2016. Visa Honkanen has a a background in pediatrics and pediatric rheumatology. He did his pediatric rheumatology training at the Hospital for Sick Children, in Toronto, Canada. He still teaches and practices pediatric rheumatology.
Professor Robert Klempfner, MD, is a specialist in Cardiology and Internal Medicine, Director of the Cardiac Prevention and Rehabilitation Institute, Scientific Director of the ARC Digital Health Innovation Center, Director of the Israeli Center for Cardiovascular Research, a registered association conducting multi-center studies. Prof Klempfner is passionate about the use of technology in the scope of outcome improvement.
Ruth Friedel currently works at the Israel Innovation Authority, while most of her service has been in ISERD, the Israel-Europe R&I Directorate; where she has helped Israeli startups access European funding Programs in Horizon2020 (the general European framework program for R&D). Recently Ruth has begun a position involved in the formation of a new Planning Unit in the International Collaborations Division, which will actively seek to connect international activity to Israel's Innovation Strategy. Previously Ruth has served as a trade officer in the commercial department of the Mission of Israel to the EU, and as a research analyst in the Israeli government. Ruth has an MA in European Studies and in Law.
Minna Hendolin, PhD in biochemistry and molecular biology, has influenced health sector research, innovation and business ecosystem while serving in multiple roles over the last 25 years. Starting from academic research, continuing with commercialization of her own research findings, and proceeding all the way up to a position in a listed multinational biopharmaceutical company, and an influencer of global innovation policy. She has several years management and leadership experience both in SMEs and large corporations as well as in a public organization. Since 2010 Dr. Hendolin has been working as a health and life science executive, focusing on government funding and innovation, first at Tekes and later at Business Finland. At her current position as Senior Director, she is leading the Health and Wellbeing thematic area at Business Finland, covering innovation and export programs, international collaboration, funding, and national strategic initiatives and policies. Dr. Hendolin belongs to the World Economic Forum Expert Group and is a regular speaker at Horasis Global Leaders Summit.
Harry Brade is a Partner at M&M Growth Partners, a Finnish Venture and Growth Capital company investing in SW companies, especially those at the crossroad of healthcare and IT and artificial intelligence in general. Harry aims to impact the ecosystem through work as an active board member at startups and governmental programs, and as Chairman of the Board of Siili Solutions Oyj, a publically listed IT company. Harry also serves as Chairman of Medical Investment Trust Oy, a closed-end fund focusing on global healthcare and pharma; and which has consistently been a top performer in its peer group and one of the first funds in Finland in this sector.
Arnaud Autret, PhD, MSc in Finance, joined the Life Science team as an Investment Principal in March 2019. Previously, he worked at Seventure Partners (Paris, France) as Senior Associate, where he invested in Life Sciences companies (microbiome applications in all fields, Digital-Health, Medtech, etc.). Before joining Seventure in 2014, Arnaud was a financial auditor associate at KPMG in the healthcare business unit (Paris, France). Arnaud received his Ph.D. in Immunology from the Pasteur Institute (Paris, France) and continued his scientific career with post-doctoral work at Trinity College (Dublin, Ireland). He gained his MSc in Finance from ESCP Europe (Paris, France). Arnaud is based in Amsterdam.